1. COG

    Comments Leave a Comment

    1-15 of 89 1 2 3 4 5 6 »
    1. Mentioned In 89 Articles

    2. A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

      ...Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL A phase 3 randomized study (COG ANBL0032) demonstrated significantly improved outcome by adding immunotherapy with ch14.18 antibody to iso...
      Read Full Article
      Mentions: Antibody COG
    3. New study by MIT Sloan researchers provides insights on the challenges of developing drugs for pediatric cancer--and offers a potential solution

      New study by MIT Sloan researchers provides insights on the challenges of developing drugs for pediatric cancer--and offers a potential solution
      ...graduate, Dr. Peter Adamson, Professor of Pediatrics and the Children's Hospital of Philadelphia and Chair of Children's Oncology Group, and Dr. Raphaël Rousseau, Chief Medical Officer at Gritstone Oncology—ran several ...
      Read Full Article
      Mentions: COG
    4. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.

      ...chemotherapy and determine if the addition of intravenous gammaglobulin (IVIG) further improves response, the Children's Oncology Group designed a randomized therapeutic trial. Eligible subjects were randomized to receiv...
      Read Full Article
      Mentions: COG Chemotherapy
    5. Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States.

      ...tal records and treating physicians contacted for verification. Application of the Children's Oncology Group (COG)'s 3-level (low, intermediate and high) neuroblastoma risk classification system for therapeutic decision-...
      Read Full Article
      Mentions: Treatment COG MYCN
    6. Neuroblastoma Patients' KIR and KIR-ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.

      ...Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman A, Yu AL, Sondel PM In 2010, a Children's Oncology Group (COG) phase III randomized trial for high-risk neuroblastoma patients (ANBL0032) demonstrated improved event-fr...
      Read Full Article
      Mentions: COG Immunotherapy
    7. Validation of post-induction Curie scores in high risk neuroblastoma. A Children's Oncology Group (COG) and SIOPEN group report on SIOPEN/HR-NBL1.

      ...guanidine (mIBG) scoring method (Curie scoring, CS) was previously examined in the Children's Oncology Group (COG) high risk neuroblastoma trial, COG A3973 (A Randomized Study of Purged vs. Unpurged Peripheral Blood Stem...
      Read Full Article
      Mentions: Staging SIOPEN COG
    8. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.

      ...ing a large recent cohort of patients with recurrent/refractory neuroblastoma from Children's Oncology Group (COG) modern-era early-phase trials, the authors determined outcome and quantified parameters for designing fut...
      Read Full Article
      Mentions: COG Refractory MYCN
    9. Children's Hospital of Philadelphia to Lead New Pediatric Data Resource Center for Research in Childhood Cancer and Structural Birth Defects

      Children's Hospital of Philadelphia to Lead New Pediatric Data Resource Center for Research in Childhood Cancer and Structural Birth Defects
      ...th defects, including data from neuroblastoma samples collected by CHOP oncologist Dr. John Maris through the Children's Oncology Group and structural birth defect and cancer samples collected by Dr. Hakon Hakonarson of ...
      Read Full Article
    10. NCI-COG Pediatric MATCH Trial to Test Targeted Therapies

      NCI-COG Pediatric MATCH Trial to Test Targeted Therapies
      ...s. For more information about NIH and its programs, visit nih.gov. About the Children’s Oncology Group (COG): COG, a member of NCI’s National Clinical Trials Network (NCTN), is the world’s largest organization devoted ex...
      Read Full Article
      Mentions: Treatment COG
    11. NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers

      NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers
      ...s. For more information about NIH and its programs, visit nih.gov. About the Children’s Oncology Group (COG): COG, a member of NCI’s National Clinical Trials Network (NCTN), is the world’s largest organization devoted ex...
      Read Full Article
      Mentions: Treatment COG
    12. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

      ...n of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Cancer. 2017 Jul 11;: Authors: Campbell K, Gastier-Foster JM, Mann M, Naranj...
      Read Full Article
      Mentions: Staging COG MYCN
    13. HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.

      ... and KIR-ligands for patients in two monoclonal antibody (mAb)-based trials: (1) A Children's Oncology Group (COG) trial for children with high-risk neuroblastoma randomized to immunotherapy treatment with dinutuximab (a...
      Read Full Article
      Mentions: COG Immunotherapy
    14. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.

      ...roblastoma. For this open-label, randomised, phase 2 selection design trial of the Children's Oncology Group (COG; ANBL1221), patients had to have histological verification of neuroblastoma or ganglioneuroblastoma at dia...
      Read Full Article
      Mentions: COG Refractory MYCN
    15. A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111)

      The c-Met receptor tyrosine kinase is dysregulated in many pediatric cancers. Tivantinib is an oral small molecule that inhibits the c-Met receptor tyrosine kinase. A phase 1 and pharmacokinetic (PK) trial evaluating tivantinib was conducted in children with relapsed/refractory solid tumors.
      Read Full Article
      Mentions: COG Refractory
    16. 1-15 of 89 1 2 3 4 5 6 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video